capacity is mediated primarily through the production of IL-10. Here we demonstrate that the induction of a regulatory program in human B cells is dependent on a metabolic priming event driven 25 by cholesterol metabolism. Synthesis of the metabolic intermediate geranylgeranyl pyrophosphate (GGPP) was required to specifically drive IL-10 production, and to attenuate Th1 responses.
Introduction
Immunosuppressive B cells form a critical component of the immune regulatory compartment 1,2 . It is thought that their suppressive capacity derives mainly from their ability to produce IL-10, and in the absence of any lineage marker, this is considered a hallmark of regulatory B cells [3] [4] [5] [6] . Their functional importance has been well described in murine models of disease, demonstrating a potent regulatory capacity across a number of contexts including infection, cancer, and autoimmune disease 3, [7] [8] [9] [10] .
Cholesterol metabolism drives IL-10 independent of B cell population
We next aimed to understand how cholesterol metabolism was able to mediate IL-10 production.
Certain populations of human B cells have been proposed as primary producers of IL-10. The most 105 well characterized of these are CD24 hi CD27 + (B10) and CD24 hi CD38 hi B cells 5, 6 . In agreement with previous observations, tSNE analysis demonstrated that all populations measured (B10, CD24 hi CD38 hi , naïve, memory, and plasmablast) contribute to the pool of IL-10 expressing cells to varying degrees (IL-10 + cells ranging from 1-12% of B cell populations, Supplementary Figure 4A ). Furthermore, B10 and CD24 hi CD38 hi B cells produced higher levels (2-3- Figure 4G ). Therefore, these data indicated a role for cholesterol metabolism in regulating IL-10 production that is shared across B cell populations, rather than an effect on specific populations.
Cholesterol metabolism drives IL-10 via geranylgeranyl pyrophosphate 120
To more precisely understand the mechanistic control by cholesterol metabolism, we next sought to investigate if a specific pathway metabolite downstream of HMG-CoA was regulating IL-10.
Cholesterol metabolism encompasses a number of metabolic pathways implicated in immune function including mevalonate, isoprenyl and sterol metabolism ( Supplementary Figure 1) , all of which are attenuated by HMG-CoA reductase inhibition to varying degrees. Given that defects in the isoprenyl 125 branch have been demonstrated to result in hyperinflammatory responses in vivo 23, 26 , we investigated if isoprenylation was regulating IL-10. To this end, we targeted geranylgeranyltransferase (GGTase) and farnesyltransferase (FTase), enzymes known to post-translationally modify proteins with geranylgeranyl pyrophosphate (GGPP) or farnesyl pyrophosphate (FPP) groups respectively (enzymes and metabolites outlined in Figure 2A ). Inhibition of GGTase, but not FTase, prevented 130 TLR9-induced IL-10 production, indicating that geranylgeranyl dependent modifications regulate IL-10 expression ( Figure 2B, Supplementary Figure 5A ). In keeping with the effects of HMG-CoA reductase inhibition, inflammatory cytokine production was preserved ( Figure 2C ). To support the notion of GGPP dependency, we depleted metabolites within the pathway with atorvastatin, and found that specifically supplementing the geranyl branch with exogenous GGPP prevented the 135 blockade of IL-10 production ( Figure 2D, Fig S5B) . Finally, to understand if cellular utilization of GGPP was dependent on the enzymatic activity of GGTase, we supplied cells with exogenous GGPP together with inhibition of GGTase. We found that GGPP was unable to rescue levels of IL-10 ( Figure 2E ), consistent with the idea that both GGTase activity and GGPP sufficiency are required for TLR9 induced expression of IL-10.
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Geranylgeranyl pyrophosphate regulates signaling through TLR9
Isoprenyl modifications almost exclusively regulate the localization of Ras superfamily proteins 27 .
Ras-dependent pathways downstream of TLR9 include Raf-MEK-ERK and PI3K-AKT cascades ( Figure 3A ). Signaling through both pathways is critically required for IL-10 production, as inhibition 145 of either pathway is sufficient to block TLR9-dependent IL-10 induction ( Figure 3B -C). Therefore, we sought to address if activation of these pathways is dependent on GGPP. Following GGTase inhibition, AKT phosphorylation on Ser473 was severely impaired, whereas ERK phosphorylation was modestly reduced at early timepoints ( Figure 3D targeting Ser9 28 . In keeping with the idea that GSK3 suppression is required for IL-10 production, chemical inhibition of GSK3 enhanced TLR9-induced IL-10 expression ( Figure 3E ). Blocking GGTase activity resulted in reduced Ser9 phosphorylation on GSK3. This indicated preserved activation of GSK3, and that GGTase activity negatively regulates GSK3, which in turn is necessary for IL-10 production ( Figure 3F ). We then examined if inhibition of GSK3 was sufficient to rescue an 155 upstream perturbation of geranylgeranylation. Indeed, bypassing GGTase through GSK3 inhibition was able to fully rescue IL-10 expression, without affecting TNFa ( Figure 3G ). Together these data suggest that following TLR9 engagement, IL-10 induction through AKT-GSK3, and possibly ERK, is dependent on GGTase activity.
PI3Kd regulates IL-10 expression in human and murine B cells
We next aimed to determine how geranylgeranyl-driven phosphorylation cascades regulate AKT-GSK3 signaling. PI3K mediates Ras-dependent AKT signaling, which suggests that isoprenylationdriven phosphorylation cascades through AKT are dependent on PI3K activity. Accordingly, pan inhibition of PI3K blocked expression of IL-10 upon TLR9 stimulation ( Figure 4A ). We found, by 165 selective inhibition of either d, a, or g isoforms of PI3K, that IL-10 is primarily regulated through PI3Kd downstream of TLR9 ( Figure 4B ). To further support the importance of PI3Kd, we examined IL-10 production in splenic B cells derived from mice expressing either a hyperactive (E1020K) or catalytically inactive (D910A) PI3Kd subunit. Following TLR9 activation, presence of the hyperactive PI3Kd mutant resulted in 3-fold increased expression of IL-10, whereas the catalytically inactive PI3Kd resulted in almost a complete loss of IL-10 production ( Figure 4C ). Furthermore, and in agreement with our previous observations, TNFa production was preserved ( Figure 4C ). These data suggest that isoprenylation-dependent interactions between Ras and PI3Kd are required for IL-10 production, and likely underpin the regulatory function of B cells.
Geranylgeranyl pyrophosphate regulates IL-10 induction via BLIMP1
Currently there is no defined transcription factor that regulates IL-10 in human B cells. Therefore, we sought to understand how IL-10 is transcriptionally regulated, and to clarify the role for GGPP in this process. Stimulation of B cells in the presence of actinomycin D indicated that a transcriptional event within the first 24 hours was necessary for IL-10 production (Supplementary Figure 7A ). Therefore,
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we suspected that under conditions of GGTase inhibition, expression of a transcription factor necessary for IL-10 may be compromised. To test this, we performed RNA-sequencing on TLR9- have been shown to regulate IL-10 expression in other cell types ( Figure 5B -D, Supplementary Figure   7C ), either through activation or repression (defined in 30 ) . We decided to focus on BLIMP1 for two reasons. First, its transcript is enriched in IL-10 + human B cells 31 . Secondly, interrogation of a murine 190 B cell ChIP-and RNA-seq data set 32 demonstrated that binding of BLIMP1 to the IL10 locus correlates with increased IL-10 expression (Supplementary Figure 7D ). Consistent with these data, we observed increased expression of BLIMP1 protein within the IL-10 + B cell populations ( Figure 5E ).
To more thoroughly address its role, we performed gene targeting experiments on BLIMP1 in primary human B cells. TLR9 stimulation strongly upregulated BLIMP1 expression, whilst siRNA agreement with a central role in regulating IL-10, siRNA-mediated knockdown of BLIMP1 reduced IL-10 expression by 50-90%, whereas TNFa production was preserved ( Figure 5I ). Together, these data demonstrate that BLIMP1 regulates IL-10 in human B cells, and its expression is dependent on cholesterol metabolism for its provision of GGPP.
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Mevalonate kinase deficient patients generate poor regulatory B cell responses
Our data demonstrated that cholesterol metabolism is essential for B cell derived IL-10 production.
We therefore sought to validate our findings in the context of human inflammatory disease. To -------+  +  +  +  +  +  +   GGTi   HES1  BHLHE41  GLMP  BHLHE40  ESR2  POU6F1  PRDM2  CREM  FOXO3  NR4A3  KLF7  ARID5B  ZEB1  KLF11  HBP1  NR1D2  ZBTB1  NR3C1  NR4A2  PRDM4  MAFF  FOS  FOXO4  MXI1  THRA  JUND  FOSL2  TGIF1  TSC22D1  KLF3  MBNL2  ZBTB10  TCF7  ZNF704  DDIT3 HBP1  NR1D2  ZBTB1  NR3C1  NR4A2  PRDM4  MAFF  FOS  FOXO4  MXI1  THRA  JUND  FOSL2  TGIF1  TSC22D1  KLF3  MBNL2  ZBTB10  TCF7  ZNF704  DDIT3  KLF9  GTF2IRD1  MNT  ZBTB16  LYL1  SKI  SETDB2  ZHX2  SREBF1  RXRA  ZNF219  DNTTIP1  ATF3  AHR  HIC1  PRDM1  ZNF692  ZNF296  BCL6  BATF  RUNX1  PHF19  ETS1  GTF2I  POU2F2  SP140  PAX5  ZNF485  NME2  HNF1B  GTF3A  PA2G4  YBX1  HMGA1  TFDP1  ZNF318  SOX5  ZNF385C id Activator Repressor IL-10: Control GGTi Figure 1A) . These patients present with a complex and severe autoinflammatory syndrome 25 . We first compared peripheral regulatory B cells from MKD patients to age and sex matched healthy controls (Supplementary Figure 8A) . We observed similar frequencies of B10 cells, whereas CD24 hi CD38 hi B cells were largely absent ( Figure 6A-B ).
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This is in line with a general shift from a naïve to memory like B cell phenotype in MKD patients (Supplementary Figure 8B ). We next examined if dysregulated cholesterol metabolism in patients with MKD leads to an inability to mount an IL-10 response, which could contribute to disease persistence or exacerbation. In line with this hypothesis, MKD patients generated poor IL-10 responses after stimulation through TLR9 (30-70% reduction versus controls, Figure 6C ), whilst including a ~3-fold reduction within B10 and CD24 hi CD38 hi B cells ( Figure 6D , gating in Supplementary Figure 4B ). This defect in IL-10 production was associated with functional impairment, as MKD B cells were unable to suppress IFNg production by autologous CD4 + T cells, when compared to B cells from healthy controls ( Figure 6E ). Moreover, pre-treatment of MKD B cells with exogenous GGPP prior to co-culture, was able to restore regulatory capacity in 2 of 2 225 donors tested (Supplementary Figure 8D ), suggesting that a GGPP deficiency impairs both IL-10 expression and defective suppressive function. To examine whether MKD imposed more a systemic defect on IL-10 producing immune cells we investigated whether T cell responses from MKD patients were also defective in IL-10 expression. In contrast to B cells, T cells were able to induce effective IL-10 responses, alongside comparable levels of other cytokines including TNFa, IFNg, IL-2 and IL-Finally, to corroborate our results, we interrogated an independent dataset (GSE43553) that performed global gene expression analysis in ex vivo PBMCs from healthy controls (n=20) and MKD patients (n=8). Gene set enrichment analysis identified defective Ras (KRAS) and PI3K-Akt-mTOR signaling 235 pathways in MKD patients when compared to healthy donors, in line with our own observations ( Figure 6F) . Collectively, and consistent with our in vitro findings, these data suggest that This study provides the first description of the metabolic requirements for IL-10 producing B cells, arguing for a central reliance on cholesterol metabolism. Our data point to a model in which synthesis of GGPP prior to stimulation permits transduction of receptor signaling cascades necessary for IL-10 expression. As a consequence, the transcription factor BLIMP1 is induced, which then promotes IL-10 gene expression. We propose that this has direct relevance in vivo, as IL-10 producing B cells from 245 patients who carry mutations in the cholesterol metabolic pathway phenocopy our in vitro findings.
Investigations into B cell metabolism have focused primarily on either antibody production or activation induced metabolic reprogramming [18] [19] [20] 33 . As alluded to above, there was no understanding of the metabolic requirements for regulatory B cells. Here we demonstrate that cholesterol 250 metabolism is critical in mediating the regulatory capacity of human B cells through its control of IL-10. Interestingly, cholesterol metabolism has been implicated in regulatory T cell function through a mechanism dependent on ICOS and CTLA-4, whilst having no effect on IL-10 expression 34 .
Although the authors did not explore this, we anticipate that regulatory T cells may also possess significant GGPP dependency, as regulatory T cell function is especially reliant on PI3Kd activity 35 .
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Therefore, whilst cholesterol metabolism appears to regulate different effector molecules between the cell types, it may be that regulatory T and B cells rely more heavily on cholesterol metabolism due to the necessity for potent GGPP-dependent PI3Kd activity.
Much of the experimental data regarding immunity and metabolism have suggested a paradigm in 260 which the integration of metabolic pathways controlling cell fate arises as a direct consequence of immune cell activation. Based on the ability of cholesterol metabolism to control induction of a regulatory program in human B cells by modulating TLR9 signaling, we propose that the programming of immune responses through cholesterol metabolism may differ in this regard. We propose that isoprenyl modifications constitute a metabolic pre-programming event. This pre-direct consequence of stimulation), that has the effect of fine-tuning signaling cascades. This notion of pre-programming is consistent with data showing the GGPP-dependent constitutive localization of Ras family proteins at the cell membrane and endosomes, and that blockade of cholesterol metabolism retains Ras in the cytoplasm 36, 37 . In other words, the state of signaling intermediates is 270 preset by the state of cholesterol metabolism of the quiescent cell at any given point.
Our finding that either GGPP deficiency or inhibition of its cognate enzyme GGTase was sufficient to block IL-10 production suggested that both the metabolite and its enzyme are absolutely required for the induction of a regulatory phenotype. Notably, inhibition of FTase was unable to inhibit IL-10 275 production, likely due to the differing targets for geranylgeranylation and farnesylation 27 . This suggests that cholesterol metabolism drives the anti-inflammatory function of B cells primarily through the synthesis of the isoprenyl group GGPP. These observations contrast with previous reports suggesting that isoprenylation largely mediates the restriction of pro-inflammatory cytokines, including TNFa, IL-6, and IL-1b. It should be noted however, that these data were derived from 280 studies of murine macrophages and intestinal epithelial cells 23, 38, 39 . Nonetheless, whilst human B cells are known to co-express inflammatory cytokines TNFa and IL-6 alongside IL-10 40 , we saw no alteration in their capability to produce these upon blockade of GGTase. This suggests that proinflammatory cytokine production relies less heavily on cholesterol metabolism. Our finding that cholesterol metabolism regulates PI3K signaling may somewhat explain this, given that PI3K can 285 differentially regulate pro-versus anti-inflammatory cytokine production upon TLR ligation [41] [42] [43] .
We found that the mechanistic control of cholesterol metabolism revolves around its ability to regulate PI3Kd-AKT signaling downstream of TLR9. Although we documented expression of all isoforms of PI3K, we observed that PI3Kd, to a greater extent than PI3Ka or PI3Kg, contributed to 290 IL-10 expression in human B cells upon TLR9 ligation. This finding is consistent with a recent observation identifying IL-10 producing B cells as the primary pathological cell type in a model of activated PI3Kd syndrome, driving Streptococcus pneumoniae persistence 14 . We further suggest that GSK3 inactivation downstream of GGPP-dependent PI3Kd-AKT signaling is also required for optimal IL-10 expression. Consistent with this, AKT-driven phosphorylation of GSK3 on Ser9 is 295 known to differentially regulate cytokine production in monocytes 28 . Moreover, we observed that reduced IL-10 expression induced in the context of defective isoprenylation could be rescued through inhibition of GSK3. In line with our findings, GSK3 inhibition in both innate cells 28 and Th1/2/17 cells 44 potentiates IL-10 expression. This provides a common framework in all immune cells, whereby restriction of GSK3 activity upon receptor ligation is necessary for IL-10 expression.
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Downstream of TLR9 ligation, BLIMP1 was shown to positively regulate IL-10 expression, suggesting its role as a transcriptional regulator of IL-10 in human B cells. Analysis of publicly available ChIP-seq datasets in both murine and human B cells are in line with this finding, suggesting that IL-10 is a significantly enriched target of BLIMP1 32, 45 . This observation is reminiscent of recent 305 work highlighting the role for BLIMP1-expressing regulatory plasmablasts and plasma cells in vivo 3, 4, 46, 47 , but also in humans ex vivo 47 . Whilst this previous work provided a correlative link between BLIMP1 and IL-10, we suggest that BLIMP1 is a direct regulator of IL-10 in B cells. Therefore, it will be interesting in future work to further delineate a direct link and understand if there is a common mechanism regulating B cell derived IL-10 in both murine and human B cells. Additionally, several 310 interesting candidates such as AHR and BATF were also identified in our screen, which warrant further investigation.
To validate our findings in the context of human disease, we investigated patients with dysregulated cholesterol metabolism. MKD patients carry a mutation in the mevalonate kinase gene. As a 315 consequence, their ability to convert mevalonate to mevalonate-5-phosphate is severely impaired. In keeping with our findings following perturbation of cholesterol metabolism in healthy B cells in vitro, we observed poor regulatory responses in B cell from these patients. This anti-inflammatory defect uncovered an unappreciated dimension to the spectrum of MKD. This included a reduced ability to produce IL-10, associated with a functional impairment in restricting T cell responses. In both cases, through the pathway might be contributing. In agreement with this, MKD patients have been demonstrated to accumulate unprenylated Ras proteins 48 . To date, the causative factor driving disease pathology has been defined as excessive inflammatory cytokine production, driven through increased macrophage driven IL-1b production 23, 49 , but also through the induction of a trained immunity 325 phenotype driven by accumulated mevalonate 50 . Here we also provide evidence that CD4 + T cells in 
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In summary, these results argue that cholesterol metabolism acts as a central metabolic pathway promoting an intrinsic anti-inflammatory program in B cells, driving IL-10 production and subsequent suppression and restriction of immune responses. 
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